Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Journal of Pharmaceutical and Sciences.
Shofiatul Fajriyah
Institut Ilmu Kesehatan Bhakti Wiyata
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Evaluation of Dose Appropriateness in Patients Congestive Heart Failure and Comorbid Chronic Kidney Disease at RSUD Kabupaten Kediri Ela Agustin; Shofiatul Fajriyah; Esti Ambar Widyaningrum; Adinda Sheisella Putri; Kumala Sari Poespita Dewi Wahyuni
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 11, No 1 (2026)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v11i1.9346

Abstract

Congestive heart failure (CHF) is a chronic condition requiring long-term therapy. Patients with heart failure accompanied by comorbid chronic kidney disease (CKD) require dose adjustment to prevent drug toxicity. This study aimed to determine the therapeutic profile and dosing appropriateness among patients with congestive heart failure and comorbid CKD hospitalized at RSUD Kabupaten Kediri during the January–December 2022 period. This study employed a retrospective observational design using medical record data with a total sampling technique, resulting in 72 eligible patients. Dose appropriateness was evaluated based on estimated glomerular filtration rate (eGFR) calculated using the Cockcroft–Gault equation and compared with recommendations from The Renal Drug Handbook. The results indicate that the majority of samples in this study were female (54.17%) and aged 45–54 years (41.67%). Most patients had additional comorbidities (80.56%), with anaemia being the most prevalent concomitant condition. Based on CKD staging, the majority of patients were classified as stage 5 CKD (77.78%). Combination therapy involving two medications was the most common treatment pattern (30.57%), with a diuretic plus ARB combination being the most frequently prescribed regimen. The evaluation of dosing appropriateness demonstrated that 69 patients (95.83%) received doses adjusted appropriately to their renal function, while 3 patients (4.17%) received inappropriate dosing. Inappropriate use was identified in prescriptions of spironolactone and acarbose, which should be avoided in patients with low eGFR values. In conclusion, most patients with congestive heart failure and comorbid CKD received therapy with doses appropriately adjusted to renal function. However, cases of inappropriate dosing were still identified, which may increase the risk of adverse effects.
Pengaruh Terapi Atorvastatin terhadap Kadar Glukosa Darah pada Pasien Stroke Iskemik dengan Diabetes Melitus yang Dirawat di Rumah Sakit Dwi Evi Diyan Sari; Erni Anika Sari; Faizatul Fitria; Hariyani Hariyani; Krisogonus Ephriono Seran; Shofiatul Fajriyah; Yogi Bhakti Marhenta; Alissya Okta Nanda Agustina
Journal of Pharmaceutical and Sciences JPS Volume 9 Nomor 3 (2026)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v9i3.1481

Abstract

Background: The use of atorvastatin in patients with stroke as a primary preventive therapy may be associated with an increased risk of elevated blood glucose levels. This study aimed to evaluate the effect of atorvastatin on changes in blood glucose levels in patients with ischemic stroke. Methods: An analytical observational study with a retrospective design was conducted among 28 hospitalized patients with ischemic stroke at Bhayangkara Hospital, Kediri City, from March to April 2024. Inclusion criteria comprised patients aged >15 years, with a history of diabetes mellitus, receiving atorvastatin therapy, and having available blood glucose data before and three days after treatment initiation. Data were analyzed using the Shapiro–Wilk test to assess normality and the paired sample t-test to evaluate changes in blood glucose levels. Results: A total of 64,29% of patients experienced an increase in blood glucose levels; however, statistical analysis demonstrated no significant difference between blood glucose levels before and after atorvastatin administration (231.64 ± 99.039 vs 231.50 ± 61.425 mg/dL; Δ = −0.14 mg/dL; p= 0.993). Conclusion: Atorvastatin therapy was not associated with statistically significant changes in random blood glucose levels. However, the high proportion of patients with increased blood glucose warrants further prospective investigation.
Co-Authors Adinda Sheisella Putri Alissya Okta Nanda Agustina Dwi Evi Diyan Sari Ela Agustin Erni Anika Sari Esti Ambar Widyaningrum Faizatul Fitria Hariyani Hariyani Krisogonus Ephriono Seran Kumala Sari Poespita Dewi Wahyuni Yogi Bhakti Marhenta